US Laboratory Developed Tests Market Size study, by Technology Outlook (Immunoassays, Hematology & Coagulation, Molecular Diagnostics, Microbiology, Clinical Chemistry, Histology/Cytology, Others), by Application Outlook (Oncology, Genetic Disorders/Inher

US Laboratory Developed Tests Market Size study, by Technology Outlook (Immunoassays, Hematology & Coagulation, Molecular Diagnostics, Microbiology, Clinical Chemistry, Histology/Cytology, Others), by Application Outlook (Oncology, Genetic Disorders/Inherited Disease, Infectious & Parasitic Diseases, Other Diseases) and Regional Forecasts 2022-2032.

US Laboratory Developed Tests Market is valued at approximately USD 3.47 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 7.20% over the forecast period 2024-2032. Laboratory Developed Tests, or LDTs, are diagnostic tests developed, validated, and performed in a single laboratory. These tests are often used when commercial tests are not available or do not sufficiently meet the unique needs of a patient population. They are designed to detect a wide range of illnesses, from genetic anomalies to infectious diseases. Laboratory Developed Tests are widely used when a test is needed however not yet commercially available, or when the available tests do not meet the specific requirements of a particular patient group. The rising prevalence of cancer and genetic disorders is assumed to be a factor in the market's expansion, as is the rise in the introduction of new products.

Chronic illnesses including diabetes, cancer, and heart disease are on the rise in the US population. When it comes to early identification, individualized treatment regimens, and condition monitoring, Laboratory Developed Tests can be quite helpful. The US government makes significant investments in healthcare R&D, at both the federal and state levels. The creation and uptake of LDTs will benefit both directly and indirectly from this financing. The United States boasts a sophisticated healthcare system that is well-established and home to several research institutes, cutting-edge labs, and highly skilled medical personnel. Compared to other locations, this enables the creation, validation, and use of LDTs on a bigger scale. However, the time and expense required to create and introduce new tests will rise sharply if the FDA were to impose more stringent regulations on LDTs in the future. This could inhibit creativity and hinder the expansion of the market.

Major market player included in this report are:
Quest Diagnostics Incorporated.
23andMe, Inc.
Abbott
Guardant Health
NeoGenomics Laboratories.
Illumina, Inc.
Company 7
Company 8
Company 9
Company 10

The detailed segments and sub-segment of the market are explained below:

By Technology Outlook
Immunoassays
Hematology & Coagulation
Molecular Diagnostics
Microbiology
Clinical Chemistry
Histology/Cytology
Flow Cytometry
Mass Spectroscopy
Others

By Application Outlook
Oncology
Genetic Disorders/Inherited Disease
Infectious & Parasitic Diseases
Immunology
Endocrine
Nutritional & Metabolic Disease
Cardiology
Mental/Behavioral Disorder
Pediatrics-specific Testing
Hematology/General Blood Test
Bodily Fluid Analysis
Toxicology
Other Diseases

Years considered for the study are as follows:
Historical year – 2022
Base year – 2023
Forecast period – 2024 to 2032

Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and Country level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.